Randomized Dose Ranging Study of the Reduction of Fasting and Postprandial Glucose in Type 2 Diabetes by Nateglinide (A-4166)

• DOI: 10.2337/diacare.24.7.1221
• Publication Date: 2007-03-05T22:51:27Z
• Authors: Fiona M. Gribble; Susan E. Manley; Jonathan C. Levy
• Keywords: Nateglinide; Dose-ranging study

This randomized crossover double-blind placebo-controlled study aimed to assess the efficacy of nateglinide (A-4166), a novel phenylalanine-derived insulin secretagogue, in type 2 diabetic subjects while fasting and 5 min before standard meal.A single dose (60, 120, or 180 mg) placebo was given eight diet-treated overnight-fasted patients seven breakfast. Plasma glucose, radioimmunoassay insulin, were measured at baseline for further min.The time-averaged 180-min postdose mean decrease plasma glucose concentration greater after (1.8 mmol/l; 95% CI 1.5-2.0) than (0.7 0.3-1.2) (P < 0.001). Hypoglycemia did not develop any subjects. Insulin concentrations increased 1.5-, 1.8-, 1.9-fold with 60-, 120-, 180-mg doses, respectively 0.001), peaking approximately 30 dose. Nateglinide peaked min, decreasing 21% peak by min. In meal test, increase (2.9 mmol/l, 2.3-3.6) over reduced 1.8 mmol/l 0.001) two higher doses nateglinide.A administered hyperglycemia secretion without hypoglycemia. Administered meal, postprandial excursion 64%. With its rapid onset short duration action, is promising oral prandial therapy diabetes.